Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07682337 | Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects | not yet recruiting | Phase 1 | 74 | SCBIO Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07665970 | SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 112 | Sinocelltech Ltd.INDUSTRY | 0 | Jun 26, 2026 | clinicaltrials |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection |
| not yet recruiting |
| Phase 1 |
| 40 |
| Robert Flavell, MD, PhDOTHER |
| 1 |
| Jun 24, 2026 |
| clinicaltrials |
| NCT07658677 | Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial | not yet recruiting | Phase 1 / Phase 2 | 50 | Theodore Brasky PhDOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07661797 | Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 294 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07657585 | CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors | not yet recruiting | Phase 1 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07649200 | Study of SNH-118110 in Advanced Solid Tumors(SNH-118110) | not yet recruiting | Phase 1 | 240 | ScinnoHub Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650357 | A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) | not yet recruiting | Phase 1 | 140 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650825 | OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07593144 | A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H) | not yet recruiting | Phase 1 | 156 | Foresight Therapeutics (Hefei) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622225 | SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 264 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07623707 | A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 264 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624214 | Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors | not yet recruiting | Phase 1 | 198 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624864 | A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 24 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07615660 | Clinical Study of CVL006 Combination With 9MW2821(CVL006-T1003) | not yet recruiting | Phase 1 / Phase 2 | 108 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | May 29, 2026 | clinicaltrials |
| NCT07615894 | WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) | not yet recruiting | Phase 1 | 9 | WestVac Biopharma Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07611370 | Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers | not yet recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612137 | Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 282 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07612488 | A Study of CS231295 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 42 | ThalassaX Therapeutics United States LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07596381 | FAK Inhibitor in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 75 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07594028 | Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 126 | Sinocelltech Ltd.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT07591285 | A Study of SYS6051 in Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 114 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT07587879 | Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors(mRNA-LNP) | not yet recruiting | Phase 1 / Phase 2 | 60 | IntraAb, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07582822 | JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC | not yet recruiting | Phase 1 | 60 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07566247 | A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor | not yet recruiting | Phase 1 | 96 | AkesoINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07509684 | A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 190 | Zhejiang Anglikang Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07510841 | JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR | not yet recruiting | Phase 1 / Phase 2 | 228 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT06781125 | One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 72 | Immorna Biotherapeutics, Inc.INDUSTRY | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07482319 | A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 15 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07462442 | Study of QLS5308 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 192 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07434609 | Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 150 | Nanolattix Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | not yet recruiting | Phase 1 / Phase 2 | 24 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07391644 | A Study of JSKN027 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 250 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07363369 | Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT07339748 | A Clinical Study of ZL-85FA Tablets | not yet recruiting | Phase 1 / Phase 2 | 51 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07327294 | A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 150 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07275853 | Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07272590 | Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 290 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07249892 | A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases | not yet recruiting | Phase 1 / Phase 2 | 195 | Chengdu Syncor Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07245901 | Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 2, 2026source: clinicaltrials